查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401005

迟发性运动障碍治疗市场，按治疗类型、药物、分布、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Tardive Dyskinesia Therapeutics Market, By Treatment Type, By Drug, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 300 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022 年迟发性运动障碍治疗市场规模为 23.4 亿美元，2023 年至 2030 年复合CAGR为 9.1%。

迟发性运动障碍治疗市场-市场动态

越来越多地认识到该疾病对患者健康的影响，以推动市场需求

随着大众和医学专业人士认识的不断加深，人们更加重视 TD 症状的早期发现和治疗。这鼓励製药公司进行包括 VMAT2 抑制剂在内的新型治疗研究和开发，以满足未满足的医疗需求。此外，监管机构对加快 TD 药物审批的支持强调需要为个人提供安全有效的选择。为了提高患者的生活品质并减少这种运动障碍的影响，我们共同努力开发 TD 治疗方案。

迟发性运动障碍治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球迟发性运动障碍治疗市场在预测期内（2023-2030）每年将以 9.1% 左右的CAGR成长

由于人们越来越认识到迟发性运动障碍对患者健康的影响，迟发性运动障碍治疗行业预计将以显着的速度增长

根据治疗类型细分，预计药物疗法将在 2022 年显示最大的市场份额

依药物细分，2022年丁苯那嗪为主导型

按地区划分，北美是 2022 年的主要收入来源

迟发性运动障碍治疗市场区隔分析：

全球迟发性运动障碍治疗市场根据治疗类型、药物、分布和地区进行细分。

根据治疗类型，市场分为两类：药物治疗、非药物治疗。药物疗法主导市场。治疗迟发性运动障碍 (TD) 的药物治疗需求量大。为了控制 TD 症状，患者寻求有效的药物，例如 VMAT2 抑制剂和抗精神病药物改良药物。製药业致力于开发安全且量身定制的药物，以满足 TD 治疗中对更好药物选择不断增长的需求。

市场依药物分为三类：Deutetrabenazine、Valbenazine、其他。丁苯那嗪产业在市场中占据主导地位，并可能在预测期内保持其主导地位。 Deutetrabenazine 是一种 VMAT2 抑制剂，在迟发性运动障碍 (TD) 的治疗中越来越受欢迎。它调节多巴胺水平的能力为有效治疗 TD 症状提供了希望。随着患者和医疗保健专业人员寻求新颖的解决方案，对氘代丁苯那嗪的需求凸显了其作为 TD 管理中有益治疗选择的潜力。

迟发性运动障碍治疗市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太地区以及中东和非洲地区。这些区域根据开展业务的国家进一步划分。北美迟发性运动障碍 (TD) 药物市场受到多种变数的影响。该地区有大量服用抗精神病药物的人群，这增加了 TD 的风险。医疗保健专业人员和患者对 TD 影响的认识不断增强，因此有必要开发适当的疗法。监管部门的批准加快了新药的上市。完善的製药业和广泛的医疗保健系统有助于 TD 药物的研究、开发和传播。需要抗精神病治疗的精神疾病频率的增加强调了解决 TD 的必要性，使北美成为旨在控制和减少 TD 症状的新药物的重要市场。

迟发性运动障碍治疗市场-竞争格局：

迟发性运动障碍 (TD) 治疗领域的主要製药参与者包括 Neurocrine Biosciences、Teva 和 Bausch Health。这些公司处于 VMAT2 抑制剂和抗精神病药物改良领域的前沿。治疗效果、安全性和市场渗透率都是市场竞争力的重要因素。这种竞争是由临床研究、政府批准和行销措施决定的。利基市场参与者专注于新颖的非药理学技术。合作与协作促进创新疗法的研究与发展。竞争环境是动态的，患者人数不断增加，意识不断增强，寻求满足 TD 患者未满足的需求，并提供有效的解决方案来控制这种复杂的运动状况。

最近的发展：

2023 年 5 月，在迟发性运动障碍意识週期间，Neurocrine Biosciences, Inc. 强调将继续支持提高人们对迟发性运动障碍 (TD) 筛检的盛行率、影响和相关性的认识。 TD 是一种因长期使用某些用于治疗忧郁症、精神分裂症、躁郁症和分裂情感性疾患的精神健康药物（抗精神病药物）而引起的不自主运动状况。

目录

第一章：迟发性运动障碍治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按治疗类型分類的迟发性运动障碍治疗市场片段
    • 迟发性运动障碍治疗市场片段（按药物）
    • 迟发性运动障碍治疗市场片段（依分布）
    • 迟发性运动障碍治疗市场片段（依国家/地区）
    • 按地区分類的迟发性运动障碍治疗市场片段
  • 竞争洞察

第 3 章：迟发性运动障碍治疗主要市场趋势

  • 迟发性运动障碍治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 迟发性运动障碍治疗市场限制
    • 市场限制影响分析
  • 迟发性运动障碍治疗市场机会
  • 迟发性运动障碍治疗市场未来趋势

第 4 章：迟发性运动障碍治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：迟发性运动障碍治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：迟发性运动障碍治疗市场格局

  • 迟发性运动障碍治疗市占率分析，2022 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：迟发性运动障碍治疗市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 药物治疗
    • 非药物疗法

第 8 章：迟发性运动障碍治疗市场 - 按药物

  • 概述
    • 按药物分類的细分市场份额分析
    • 丁苯那嗪
    • 缬苯那嗪
    • 其他的

第 9 章：迟发性运动障碍治疗市场 - 按分布

  • 概述
    • 按分布分類的细分市场占有率分析
    • 医院药房
    • 药局和零售药局
    • 网路药局

第 10 章：迟发性运动障碍治疗市场 - 依地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 迟发性运动障碍治疗北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模和预测（按药物）
    • 北美市场规模和预测（按分布）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲迟发性运动障碍治疗药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模与预测（按药品）
    • 欧洲市场规模与预测（按分布）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 迟发性运动障碍治疗药物亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区药物市场规模与预测
    • 亚太地区市场规模与预测（按分布）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 迟发性运动障碍治疗药物拉丁美洲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按药品）
    • 拉丁美洲市场规模与预测（按分布）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 迟发性运动障碍治疗药物中东和非洲主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按治疗类型）
    • 中东和非洲市场规模及预测（按药品）
    • 中东和非洲市场规模及预测（按分布）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 迟发性运动障碍治疗产业

  • 竞争仪表板
  • 公司简介
    • Neurocrine Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Sunovion Pharmaceuticals Inc.
    • Teikoku Pharma USA, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Neurolixis, Inc.
    • Retrophin, Inc.
    • NeuroSearch A/S
    • Abide Therapeutics, Inc.
    • Cynapsus Therapeutics Inc.
    • Ichor Medical Systems
    • Reviva Pharmaceuticals Inc.
    • Acorda Therapeutics, Inc.
    • Adamas Pharmaceuticals, Inc.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1969

REPORT HIGHLIGHT

Tardive Dyskinesia Therapeutics Market size was valued at USD 2,340 Million in 2022, expanding at a CAGR of 9.1% from 2023 to 2030.

Tardive Dyskinesia (TD) treatments are medical procedures that try to relieve the uncontrollable and irregular movements that might occur as a consequence of long-term usage of certain antipsychotic medicines. These therapy techniques include pharmaceutical therapies such as antipsychotic adjustments or VMAT2 inhibitors, which aid in the management of TD symptoms. Non-pharmacological treatments such as behavioral counseling and deep brain stimulation can additionally be used. The purpose of TD therapies is to reduce or eliminate the disruptive motor manifestations of TD, therefore enhancing patients' general level of life and giving respite from the sometimes-upsetting symptoms of this medication-induced mobility disorder.

Tardive Dyskinesia Therapeutics Market- Market Dynamics

Increasing recognition of the condition's impact on patients' well-being to propel market demand

As public and medical professional understanding grows, there is a greater emphasis on early detection and treatment of TD symptoms. This encourages pharmaceutical companies to conduct novel therapeutic research and development, which includes VMAT2 inhibitors, to address unmet medical needs. Furthermore, regulatory authorities' support for expediting TD drug approval stresses the need to offer individuals safe and effective choices. The collaborative efforts to develop TD treatment options are driven by a desire to enhance patient's quality of life and reduce the effect of this movement disorder.

Tardive Dyskinesia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Tardive Dyskinesia Therapeutics market is estimated to grow annually at a CAGR of around 9.1% over the forecast period (2023-2030)

The Tardive Dyskinesia Therapeutics industry is projected to grow at a significant rate due to increasing recognition of the condition's impact on patients' well-being

Based on Treatment Type segmentation, Pharmacological Therapies was predicted to show maximum market share in the year 2022

Based on Drug segmentation, Deutetrabenazine was the leading type in 2022

On the basis of region, North America was the leading revenue generator in 2022

Tardive Dyskinesia Therapeutics Market- Segmentation Analysis:

The Global Tardive Dyskinesia Therapeutics Market is segmented on the basis of Treatment Type, Drug, Distribution, and Region.

The market is divided into two categories based on Treatment Type: Pharmacological Therapies, Non-pharmacological Therapies. The Pharmacological Therapies dominates the market. Pharmacological medications are in high demand in the treatment of Tardive Dyskinesia (TD). To control TD symptoms, patients seek effective drugs such as VMAT2 inhibitors and antipsychotic modifications. The pharmaceutical industry is focused on creating safe and tailored medicines to meet the rising need for better pharmacological choices in TD therapy.

The market is divided into three categories based on Drug: Deutetrabenazine, Valbenazine, Others. The Deutetrabenazine sector dominates the market and is likely to maintain its dominance during the forecast period. Deutetrabenazine, a VMAT2 inhibitor, is becoming more popular in the treatment of Tardive Dyskinesia (TD). Its capacity to modulate dopamine levels provides promise for efficiently treating TD symptoms. The demand for deutetrabenazine highlights its potential as a beneficial treatment option in TD management as patients and healthcare professionals seek novel solutions.

Tardive Dyskinesia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. A variety of variables influence the market for Tardive Dyskinesia (TD) medicines in North America. The area has a large population on antipsychotic drugs, which raises the risk of TD. The growing awareness of the effects of TD among healthcare professionals and patients necessitates the development of appropriate therapies. Regulatory approval expedites the availability of novel medicines. The well-established pharmaceutical industry and extensive healthcare system assist TD medicinal research, development, and dissemination. The increased frequency of mental illnesses requiring antipsychotic treatment emphasises the need of addressing TD, making North America a critical market for novel medications targeted at controlling and reducing TD symptoms.

Tardive Dyskinesia Therapeutics Market- Competitive Landscape:

Key pharmaceutical participants in the Tardive Dyskinesia (TD) treatment landscape include Neurocrine Biosciences, Teva, and Bausch Health. These firms are at the forefront of VMAT2 inhibitors and antipsychotic modifications. Treatment effectiveness, safety profiles, and market penetration are all important factors in market competitiveness. The rivalry is shaped by clinical studies, governmental approvals, and marketing initiatives. Niche players concentrate on novel non-pharmacological techniques. Collaborations and collaborations foster innovative therapy research and development. The competitive climate is dynamic, with a rising patient population and increased awareness seeking to meet unmet requirements of TD patients and deliver effective solutions for controlling this complex movement condition.

Recent Developments:

In May 2023, During Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. highlighted its continuing support for raising awareness about the prevalence, impact, and relevance of screening for tardive dyskinesia (TD). TD is an involuntary movement condition caused by long-term use of certain mental health medications (antipsychotics) intended to treat depression, schizophrenia, bipolar disorder,and schizoaffective disorder.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET KEY PLAYERS

  • Neurocrine Biosciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teikoku Pharma USA, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neurolixis, Inc.
  • Retrophin, Inc.
  • NeuroSearch A/S
  • Abide Therapeutics, Inc.
  • Cynapsus Therapeutics Inc.
  • Ichor Medical Systems
  • Reviva Pharmaceuticals Inc.
  • Acorda Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY TREATMENT TYPE

  • Pharmacological Therapies
  • Non-pharmacological Therapies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DRUG

  • Deutetrabenazine
  • Valbenazine
  • Others

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISTRIBUTION

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Tardive Dyskinesia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Tardive Dyskinesia Therapeutics Market Snippet by Treatment Type
    • 2.1.2. Tardive Dyskinesia Therapeutics Market Snippet by Drug
    • 2.1.3. Tardive Dyskinesia Therapeutics Market Snippet by Distribution
    • 2.1.4. Tardive Dyskinesia Therapeutics Market Snippet by Country
    • 2.1.5. Tardive Dyskinesia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Tardive Dyskinesia Therapeutics Key Market Trends

  • 3.1. Tardive Dyskinesia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Tardive Dyskinesia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Tardive Dyskinesia Therapeutics Market Opportunities
  • 3.4. Tardive Dyskinesia Therapeutics Market Future Trends

4. Tardive Dyskinesia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Tardive Dyskinesia Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Tardive Dyskinesia Therapeutics Market Landscape

  • 6.1. Tardive Dyskinesia Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Tardive Dyskinesia Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2022 & 2030 (%)
    • 7.1.2. Pharmacological Therapies
    • 7.1.3. Non-pharmacological Therapies

8. Tardive Dyskinesia Therapeutics Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
    • 8.1.2. Deutetrabenazine
    • 8.1.3. Valbenazine
    • 8.1.4. Others

9. Tardive Dyskinesia Therapeutics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Drug Stores & Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Tardive Dyskinesia Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Tardive Dyskinesia Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Tardive Dyskinesia Therapeutics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Neurocrine Biosciences, Inc.
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.3. Bausch Health Companies Inc.
    • 11.2.4. Sunovion Pharmaceuticals Inc.
    • 11.2.5. Teikoku Pharma USA, Inc.
    • 11.2.6. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.7. Neurolixis, Inc.
    • 11.2.8. Retrophin, Inc.
    • 11.2.9. NeuroSearch A/S
    • 11.2.10. Abide Therapeutics, Inc.
    • 11.2.11. Cynapsus Therapeutics Inc.
    • 11.2.12. Ichor Medical Systems
    • 11.2.13. Reviva Pharmaceuticals Inc.
    • 11.2.14. Acorda Therapeutics, Inc.
    • 11.2.15. Adamas Pharmaceuticals, Inc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Tardive Dyskinesia Therapeutics Market: Treatment Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment Type
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Treatment Type 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Drug Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Drug 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Distribution Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Distribution 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)